Transgene S.A. Stock
€1.84
Your prediction
Transgene S.A. Stock
Pros and Cons of Transgene S.A. in the next few years
Pros
Cons
Performance of Transgene S.A. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Transgene S.A. | -0.430% | 1.314% | -6.377% | -19.037% | 11.985% | 54.167% | -36.968% |
Erytech Pharma S.A. | -5.110% | 18.123% | 5.632% | -42.274% | 153.308% | - | - |
Nanobiotix | -2.260% | 3.750% | -2.639% | -48.287% | -6.347% | -39.361% | -73.776% |
Avadel Pharmaceuticals plc ADR | -1.760% | 3.125% | -12.698% | - | 27.907% | - | - |
Comments
News

Transgene Announces Upcoming Investor Meetings
Regulatory News:
TRANSGENE (Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces that Management will participate in

Transgene: 2022 Full-year Results and Business Update
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today publishes its financial

Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will be presenting eight posters